AREAS OF INTEREST

Bone, Respiratory, Immunology,
and Endocrine

  • Arthritis and Immune-Based Diseases

    Areas of Interest:

    • Disease-modifying antirheumatic drugs or mechanisms with clinical proof of concept
      • Biologics superior to TNF sequestrants
      • Novel oral DMARDS with equivalent or superior efficacy to TNF sequestrants
      • Selective glucocorticoid modulators
      • Syk or JAK inhibitors
      • Th17 pathway modulators
    • Disease-modifying osteoarthritis drugs with clinical proof of concept
    • Cartilage / joint imaging technologies
    • Immunomodulators for psoriasis, SLE, or IBD in Phase IIb or later

    Not Interested in:

    • Broadly immunosuppressant mechanisms
    • Calcineurin inhibitors

  • Asthma / COPD

    Areas of Interest:

    • Compounds / biologics for asthma
      • Anti-inflammatory agent with novel mechanism
      • Anti-inflammatory agent additive or differentiated from a glucocorticoid
      • Selective glucocorticoid receptor modulators
      • Novel and / or differentiated bronchodilator mechanisms
      • Inhaled compounds including combination therapies
    • Compounds / biologics for COPD with clinical proof of concept
      • Inhaled compounds including combination therapies
    • Compounds for rhinitis, atopic dermatitis, and allergy
    • Technologies
      • Biomarkers
      • Predictive animal models of asthma pathophysiology
      • Translational medicine platforms
      • Inhaled technologies / formulations that provide improved drug delivery / compliance / patient acceptance

    Not Interested in:

    • Acute lung injury
    • Antioxidants (ie, direct scavengers)
    • Adenosine antagonists (A1, A2, and A3)
    • CCR3 and CCR4 antagonists
    • Antihistamine antagonists (H1, H2)
    • IL5 antagonists
    • Leukotriene antagonists
    • VLA4 antagonists

  • Bone

    Areas of Interest:

    • Osteoanabolic agents
      • Novel mechanisms with known molecular target
    • Biomarkers
      • Surrogate biomarkers of bone strength and / or fracture risk
      • More sensitive and faster biomarkers of bone anabolism
      • Selective markers for corticol and trebecular bone anabolism
      • Markers for specific bone loss / fracture risk in:
        • Postmenopausal and male osteoporosis
        • Glucocorticoid osteoporosis
        • Cancer-related bone loss
    • Novel bone imaging technologies and measures of bone quality
    • Osteoporosis diagnostics
      • Self-assessment tools
      • Inexpensive BMD / BMx and fracture risk measures

    Not Interested in:

    • Growth hormone or derivatives by any route
    • ER alpha agents
    • Classic "antiresorptive agents," including bisphosphonates with improved formulations that allow less frequent dosing or better tolerability

  • Sarcopenia

    Areas of Interest:

    • Mechanisms that preserve / restore fibers (both biologics and small molecule)
      • Myoanabolic agents (antimyostatin)
        • Satellite cell maintenance / proliferation
      • Anticatabolic agents
    • Mechanisms that improve fiber function (both biologics and small molecule)
      • Neuromuscular junction / alpha motor unit maintenance
      • Fiber recruitment
      • Fiber type switching
      • Fiber metabolism
      • Sarcomere dysfunction
    • Biomarkers and diagnostics
      • Biochemical markers of muscle functional state (remodeling, metabolism)
      • Imaging markers of muscle function
      • Physical tests

    Not Interested in:

    • Growth hormone (GH), growth hormone-releasing hormone (GHRH), or derivatives by any route
    • Growth hormone secretagogues

  • Urology and Women’s Health

    Areas of Interest:

    • Novel therapies for OAB (Phase I or greater)
    • Novel therapies for stress urinary incontinence (Phase I or greater)
    • Novel therapies for BPH (Phase I or greater)
    • Biomarkers
      • Surrogate biomarkers of bladder dysfunction
      • Imaging approaches for indices of bladder function, including control of bladder function
    • Diagnostics to improve specificity of diagnosing OAB from stress incontinence
    • Diagnostics to predict response or nonresponse to therapy including anticholinergics or other mechanisms of action
    • Novel therapies for endometriosis
    • Novel therapies for vasomotor symptoms

    Not Interested in:

    • Sexual dysfunction (male)

Areas of Interest

Click on the icons below for more information about your areas of interest.

Research & Enabling Technologies Atherosclerosis and Cardiovascular Diseases Biologics Respiratory and Immunology Diabetes and Endocrinology Infectious Diseases Neurosciences and Ophthalmology Oncology Therapeutics Vaccines Global Out-Licensing

Have a Discovery?

If you think something you discovered might be of interest to Merck, contact one of our scientific scouts.

Learn more about us

TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.